The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report.
A Humar; M Morris; E Blumberg; R Freeman; J Preiksaitis; B Kiberd; E Schweitzer; S Ganz; A Caliendo; J P Orlowski; et al. (Profiled Author: Dorry Segev)
Transplant Infectious Diseases, University of Alberta. firstname.lastname@example.org
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2010;10(4):889-99.
Nucleic acid testing (NAT) for HIV, HBV and HCV shortens the time between infection and detection by available testing. A group of experts was selected to develop recommendations for the use of NAT in the HIV/HBV/HCV screening of potential organ donors. The rapid turnaround times needed for donor testing and the risk of death while awaiting transplantation make organ donor screening different from screening blood-or tissue donors. In donors with no identified risk factors, there is insufficient evidence to recommend routine NAT, as the benefits of NAT may not outweigh the disadvantages of NAT especially when false-positive results can lead to loss of donor organs. For donors with identified behavioral risk factors, NAT should be considered to reduce the risk of transmission and increase organ utilization. Informed consent balancing the risks of donor-derived infection against the risk of remaining on the waiting list should be obtained at the time of candidate listing and again at the time of organ offer. In conclusion, there is insufficient evidence to recommend universal prospective screening of organ donors for HIV, HCV and HBV using current NAT platforms. Further study of viral screening modalities may reduce disease transmission risk without excessive donor loss.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
L M Kucirka; R Namuyinga; C Hanrahan; R A Montgomery; D L SegevAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009;9(5):1197-204.
L M Kucirka; C Alexander; R Namuyinga; C Hanrahan; R A Montgomery; D L SegevAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009;9(3):620-8.
Andrew L Singer; Lauren M Kucirka; Ruth Namuyinga; Colleen Hanrahan; Aruna K Subramanian; Dorry L SegevCurrent opinion in organ transplantation 2008;13(4):400-4.
Appears in this Publication
Author of this Publication